Methods and Designs of Modern Breast Cancer Confirmatory Trials
Background: The benefit–risk assessments of new drugs for breast cancer (BC) face several challenges, as all stakeholders do not agree on the evidence bar required for market authorization, and by the fragmentation of breast cancer diagnosis. The aim of this study was to describe the changes in meth...
Main Authors: | Julien Péron, Thibaut Reverdy, Colette Smenteck, Marion Cortet, Benoît You, Gilles Freyer |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/11/2757 |
Similar Items
-
Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives
by: Romain Varnier, et al.
Published: (2021-09-01) -
When do we need clinical endpoint adjudication in clinical trials?
by: Claes Held
Published: (2019-01-01) -
Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990–2011
by: Behnood Bikdeli, et al.
Published: (2017-03-01) -
Frequent fragility of randomized controlled trials for HCC treatment
by: Hao Zhang, et al.
Published: (2021-04-01) -
Food and Drug Administration approvals in phase 3 Cancer clinical trials
by: Joseph Abi Jaoude, et al.
Published: (2021-06-01)